利用现实世界的数据进行对罕见疾病进行外部控制的试验,用计数类型的终点:利用多个条目 - - 一个模拟研究
Tianyu Sun1, Eileen Liao1, Nan Shao1
1Biometrics, Moderna, Inc., Cambridge, Massachusetts, USA.
Journal of biopharmaceutical statistics
|October 27, 2024
概括
这项研究引入了一种新的临床试验设计,用于罕见疾病的真实世界数据 (RWD). 在外部控制臂中允许从RWD输入多个患者,从而提高了试验的效率和可靠性.
科学领域:
- 临床试验方法论 临床试验方法论
- 现实世界的数据分析.
- 罕见疾病研究 罕见疾病研究
背景情况:
- 对于罕见疾病的随机对照试验面临挑战,因为患者人数较少和道德问题.
- 现实世界数据 (RWD) 提供了一个可行的替代方案,用于生成支持证据,当传统试验是不可行的.
- 从RWD构建的外部控制臂 (ECA) 有时用于单臂试验,但患者在多个时间点的资格使其设计复杂化.
研究的目的:
- 提出一种新的外部控制试验设计,适应RWD患者的多个入口点.
- 推统计方法来处理混因素,小样本大小,主体内相关性和计数数据过度分散.
- 为了呈现一个适合这种新型试验设计的遮工艺.
主要方法:
- 开发一种新的外部控制试验设计,允许每位RWD患者多次输入.
- 制定统计方法,解决测量的混因素,有限的样本大小,主体内相关性和过度分散.
- 基于罕见疾病病例的模拟研究,以评估设计和方法性能与单入方法相比.
主要成果:
- 采用多个RWD输入的拟议设计显示了受控的I型错误率.
- 这些方法显示出对某些模型错误规范的稳定性.
- 与选择每个ECA患者的单个入口点相比,观察到统计功率的适度改善.
结论:
- 具有多个RWD条目的新型外部控制试验设计提高了试验性能.
- 这种方法为罕见病药物开发提供了可靠和有效的方法.
- 拟议的统计方法和遮蔽过程支持了这一设计的实施.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
01:12Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91
01:24Kaplan-Meier Approach
102
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
102
01:09Censoring Survival Data
65
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
65